- Home
- KIDS vs ABUS Comparison
KIDS vs ABUS Comparison
Compare KIDS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- ABUS
- Stock Information
- Founded
- KIDS 2007
- ABUS 2005
- Country
- KIDS United States
- ABUS United States
- Employees
- KIDS N/A
- ABUS N/A
- Industry
- KIDS Medical/Dental Instruments
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- ABUS Health Care
- Exchange
- KIDS Nasdaq
- ABUS Nasdaq
- Market Cap
- KIDS 601.5M
- ABUS 670.3M
- IPO Year
- KIDS 2017
- ABUS N/A
- Fundamental
- Price
- KIDS $20.29
- ABUS $3.43
- Analyst Decision
- KIDS Buy
- ABUS Strong Buy
- Analyst Count
- KIDS 7
- ABUS 4
- Target Price
- KIDS $35.71
- ABUS $5.50
- AVG Volume (30 Days)
- KIDS 139.2K
- ABUS 610.0K
- Earning Date
- KIDS 08-04-2025
- ABUS 07-31-2025
- Dividend Yield
- KIDS N/A
- ABUS N/A
- EPS Growth
- KIDS N/A
- ABUS N/A
- EPS
- KIDS N/A
- ABUS N/A
- Revenue
- KIDS $212,453,000.00
- ABUS $6,403,000.00
- Revenue This Year
- KIDS $19.23
- ABUS $3.35
- Revenue Next Year
- KIDS $17.14
- ABUS N/A
- P/E Ratio
- KIDS N/A
- ABUS N/A
- Revenue Growth
- KIDS 31.28
- ABUS N/A
- 52 Week Low
- KIDS $19.52
- ABUS $2.71
- 52 Week High
- KIDS $35.99
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- KIDS 40.70
- ABUS 50.84
- Support Level
- KIDS $19.99
- ABUS $3.46
- Resistance Level
- KIDS $21.55
- ABUS $3.65
- Average True Range (ATR)
- KIDS 0.78
- ABUS 0.12
- MACD
- KIDS -0.05
- ABUS -0.00
- Stochastic Oscillator
- KIDS 27.05
- ABUS 35.29
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.